PVC Benefit-Risk Assessment 3

Question 1

Which patient population factor most commonly shifts a benefit-risk balance from unfavorable to favorable for a high-risk drug?

Accepted Answer

Patients with severe, life-threatening disease with no adequate alternative therapy

Answer

For patients with serious conditions lacking alternatives, even substantial risks may be outweighed by significant clinical benefits, shifting the balance favorably.

Question 2

The EMA's Benefit-Risk Methodology Project recommended which structured framework as most suitable for regulatory benefit-risk assessment?

Accepted Answer

PrOACT-URL

Answer

The EMA Benefit-Risk Methodology Project concluded that PrOACT-URL (Problem, Objectives, Alternatives, Consequences, Trade-offs, Uncertainty, Risk tolerance, Linked decisions) is well-suited for regulatory use.

Question 3

When assessing benefit-risk for a biosimilar, which unique consideration differs from assessment of a novel drug?

Accepted Answer

Benefit-risk relies heavily on extrapolation from the reference product's established profile

Answer

Biosimilar benefit-risk assessment uses the reference product's established profile as the foundation, with extrapolation to indications based on demonstrated similarity.

Question 4

A company conducts a Periodic Benefit-Risk Evaluation Report (PBRER). The primary regulatory purpose of this document is to:

Accepted Answer

Present a cumulative reassessment of the product's benefit-risk balance at defined intervals

Answer

The PBRER provides a cumulative, interval-based benefit-risk reassessment integrating all new data to determine whether the profile remains favorable.

Question 5

Which type of risk minimization measure goes beyond the standard product label to actively restrict prescribing or dispensing?

Accepted Answer

Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU)

Answer

REMS with ETASU impose specific conditions such as certified prescribers, pharmacies, or patient enrollment to ensure safe use beyond standard labeling.

(PVC) Pharmacovigilance Certification Practice Test

(PVC) Pharmacovigilance Certification Practice Test

PVC Benefit-Risk Assessment 3